Firma meldet: Tau-Spritze senkte Tau im Nervenwasser; Haut-Uhr sank unter Creme

Tau protein in spinal fluid dropped a mean 73% in healthy volunteers after an under-the-skin shot, the maker says. Here is what that does and does not show, plus a skin epigenetic age study and AI drug discovery, in this week's longevity news. Tau protein shot (ARO-MAPT): Arrowhead says its investigational RNAi drug ARO-MAPT, given by injection under the skin, lowered tau in spinal fluid by a mean 73% at day 105 in the top-dose cohort of healthy volunteers, and by up to 85% in one person. Day 105 is about 90 days after the final dose, which the company says supports the potential for dosing about every three months. This is interim company data and a biomarker measured in healthy people. Effects on tau tangles, memory and disease progression have not been tested yet. Part 2 is enrolling people with early Alzheimer's disease. Skin epigenetic age (RLS-1496): Rubedo Life Sciences tested RLS-1496, a topical meant to clear senescent cells, in a small Phase 1b in people with atopic dermatitis (eczema). After four weeks, measured skin epigenetic age was a mean 2.1 years lower across 11 paired samples (p=0.032), and one best responder was down 11.7 years at day 63. It is company data from one aging clock. A clock reading is an estimate of biological age, not proof of visibly younger skin or a longer life. Rubedo also says a hair-loss trial is planned. AI drug discovery for aging (Deep Origin and BioAge Labs): Deep Origin says its AI virtual screening delivered multiple structurally distinct hits against a new BioAge target, picked from human aging data, in under three months. BioAge validated them in its own lab and is moving the target into hit-to-lead work. These are early lab hits, years away from any patient. Sources: https://arrowheadpharma.com/en-us/newsroom/arrowhead-pharmaceuticals-announces-aro-mapt-interim-phase-12a https://www.biospace.com/press-releases/rubedo-life-sciences-announces-phase-1b-data-showing-reduction-in-skin-epigenetic-age-and-systemic-inflammatory-biomarkers-following-four-week-treatment-with-rls-1496 https://thetechbriefs.com/deep-origin-announces-multi-target-ai-driven-drug-discovery-collaboration-with-bioage-labs-validated-hits-confirmed-against-first-target/ Follow for the longevity news every week, and tell us in the comments what you want covered next. #longevity #tauprotein #biologicalage